BioSpace News Archive

Incyte announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 Congress.

Affimed N.V. announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:00 p.m. Eastern Daylight Time / 19:00 Central European Time.

Medtronic plc and DaVita Inc. announced the intent to form a new, independent kidney care-focused medical device company to enhance the patient treatment experience and improve overall outcomes.

Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2022, which ended April 29, 2022.

Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, announced that Young T. Kwon, PhD, Alchemab’s Chief Financial and Operating Officer, has succeeded Douglas A. Treco, PhD as Chief Executive Officer and member of the Board, who resigned for personal reasons.

Bristol Myers Squibb to Participate in Bernstein’s 38th Annual Strategic Decisions Conference.

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended March 31, 2022.

VirtaMed’s VR simulations provide advanced training for surgeons using MMI’s Symani® Robotic System and introduce new product testing capabilities.

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has prioritized its clinical development portfolio after rapid enrollment for its Phase 2a clinical trial in Long COVID.

Biomind Labs Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s Disease.